A research team led by Clévio Nóbrega, professor at the Department of Biomedical Sciences and Medicine and researcher at the Center for Research in Biomedicine (CBMR) of the University of Algarve (UAlg), has just obtained funding from the French Association of Myopathies (AFM) for study, over the next two years, a new therapeutic strategy for a set of neurodegenerative diseases, called polyglutamine diseases.
According to UAlg, "so far there is no treatment for these diseases, being applied only symptomatic treatments incapable of delaying or preventing their progression".
The objective of the research, which will be carried out at the CBMR Laboratory of Molecular Neuroscience and Gene Therapy, is ambitious: to develop a new therapeutic strategy for this type of disease and to study ways to allow its translation to the clinical universe.
In the words of the researcher, «this international funding, in addition to others that we have already achieved in the past, demonstrates the quality and recognition of the research carried out at CBMR and UAlg».
Clévio Nóbrega's project begins in May this year and thus forms part of a set of innovative projects around the world that seek, through funding their research, to develop treatments and alternatives in the context of different neurodegenerative diseases.
Comments